FABP1 and metabolic dysfunction-associated steatotic liver disease: Although our findings indicate that LFABP may serve as a noninvasive biomarker for NASH, further studies are needed to establish LFABP as a reliable diagnostic marker for NAFLD and to determine its efficacy in differentiating between NASH and non-NASH.